News

Sunstone Capital portfolio company Zealand Pharma A/S and Helsinn Healthcare SA today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies.

NatImmune A/S today announced the initiation of a phase IIb clinical trial designed to evaluate the safety and efficacy of its BAMLET Tropical Gel, a protein-lipid based proprietary dermatological product candidate, for the treatment of recalcitrant warts in immuno-suppressed kidney-transplanted patient when applied locally to wart lesions.

Copenhagen, Denmark and Seattle, WA, USA, June 19, 2008—ACE BioSciences and PATH have announced a new partnership to advance the development of a promising vaccine against one of the leading bacterial causes of diarrheal disease, enterotoxigenic E.coli (ETEC). PATH will fund ACE BioSciences to complete Phase 1 and Phase 2 clinical trials up to proof of concept of its ACE527 vaccine. ACE527 offers the broadest coverage among currently available ETEC vaccine formulations, and the vaccine’s components have already been tested in more than 100 subjects.

Sunstone Capital A/S announces the Second Closing of its fundraising that began in 2007. New investors include institutional investors Sampension Private Equity F.M.B.A. and Finnish Industry Investment Ltd, as well as additional private investors, who in total have committed approximately EUR 21 million, increasing total funds under management to EUR 411 million.

Under the terms of the alliance, Nuevolution’s proprietary Chemetics® drug discovery technology will be applied to identify novel small molecule lead compounds against a range of drug targets proposed by Lexicon. Nuevolution will receive an upfront payment and will be eligible for milestone payments and royalties on compounds identified using its technology as candidate molecules progress through preclinical and clinical development and onto the market. At a future point in time, Nuevolution will have the option to expand its involvement in certain programs under a cost and profit sharing arrangement.